A central goal in the study of human biology is to understand the molecular basis of common disease, and variable sensitivity to drugs and other environmental factors. Adverse drug effects are a major cause of hospitalisation. 1 The development of more effective, safer medicines requires understanding of the genetic factors which govern variable drug response in different individuals. Recent advances in genetics and genomics are paving the way to develop diagnostic tests that will enable the administration of drugs to be tailored to groups of individuals, and may in future help to define appropriate individual dosages and drug combinations in pharmacological treatment. These hopes are reflected in the growth of pharmacogenetic and pharmacogenomic research. Here we review the potential impact of current research in human genetic variation on our understanding and management of variable drug responses.
In the past 10 years, there has been great success in identifying the genetic basis of rare Mendelian disorders through linkage studies in large affected families. The genes and underlying mutations, which cause over 1400 such conditions, are reported in OMIM (http://www.ncbi.nlm.nih.-gov). However, similar approaches have yielded much more modest success when applied to common, polygenic diseases and other phenotypes in which multiple genetic and environmental factors contribute to the risk that an individual has to develop disease. It is now widely accepted that association studies offer greater statistical power over linkage in detecting genetic effects underlying complex traits 2 when the causative variant is common in the population. This power is determined by the allele frequency and risk ratio of the causative variant in relationship to the sample size. A key element in undertaking such studies is the establishment of a comprehensive catalogue of common variants in the human population.
Detecting the clinically important genetic factors in determining variable drug response poses a similar problem. Variability in drug response is governed both by genetic variants and nongenetic factors such as diet, age and gender. The contribution of genetic factors may be classified into two groups: pharmacokinetic variants affect uptake, absorption, metabolism or clearance of a drug, and occur, for example, in genes that encode liver enzymes or drug transporters. The same genetic variants may affect the response to a range of drugs, because multiple drugs are metabolised via the same route (as in the well-known case of cytochrome P450 enzyme CYP2D6, which metabolises a quarter of all commonly used drugs). Pharmacodynamic variants affect the biological function of the drug at the site of action-for example, by altering the binding of a drug to a neurotransmitter receptor (eg variants in the GABA A receptor subunits alter responsiveness to the antiepileptic benzodiazepines). The challenges facing us in making effective use of genetic and genomic information in pharmacological applications rely on being able to discover the biologically and medically important genetic variants for each phenotype, and to apply them to improve the use of drugs in healthcare. Studies to date have mainly focused on candidate genes, each one chosen on the basis of a prior hypothesis that they encode a protein that is involved in a particular drug response. Such studies are now greatly enhanced by the wealth of information on new genes and variants that is available in the public domain as a result of the Human Genome Project and associated research. The more ambitious approach would be to scan the entire genome for important new variants-an approach which is not limited by any prior hypothesis, but which requires effective resources and technology for genome-wide analysis. But what is the best way forward, how do we make the best use of the available information, and what resources do we need to develop?
HUMAN VARIATION
Modern humans are a young species in evolutionary terms, with a limited amount of sequence variation. It has been estimated that there are 11-15 million variants with a minor allele frequency 41%. Over 90% of these variants are single-nucleotide polymorphisms (SNP). Through large-scale efforts, over 4.5 million SNPs are currently available in the public domain (dbSNP; build116). However, only a small fraction of these SNPs has been characterised in terms of allele frequency and ethnic distribution. This year has seen the completion of a highly accurate and contiguous reference sequence of the euchromatic (gene-coding) part of the human genome. A comprehensive set of annotated human genes is available, and comparative analysis of the human genome sequence to those of other species is highlighting additional evolutionary conserved regions, which are likely to be enriched in functional elements such as transcriptional regulators. As a result, we can begin to systematically explore the sequence variation content of the functional part of the genome, which recent studies estimate not to exceed 5%, in the human population.
An association study can be undertaken using either a direct or an indirect approach. The former relies on the availability of a complete list of functional variants, which are then tested for association to the trait of interest in a number of phenotypically matched cases and controls. The latter involves testing a series of genomic variants across a region (or all) of the genome for association, and relies on the assumption that the causative variant will be in linkage disequilibrium (LD) with one of the variants tested. Thus, characterisation and understanding of the dynamics of LD across the genome is necessary for enabling whole-genome association studies.
Recent studies conducted at various levels of resolution have all shown that the extent of LD in different parts of the genome is highly variable, averaging 5-20 kb but extending up to hundreds of kilobases. [3] [4] [5] Variability in average LD has also been observed between ethnic groups, owing to differences in their demographic history, for example, population bottlenecks, admixture, genetic drift and natural selection. The key observation is that present day chromosomes consist mainly of short segments that have undergone very limited or no historic recombination, and that for each of these segments a few common haplotypes represent the majority in a population. 3, 6 For each region of high LD and low haplotypic diversity (also termed a haplotype block), only a few variants are then needed to tag the common haplotypes within it. These are referred to as haplotype tag (ht) SNPs. 7 Based on this rationale, an international effort, the HapMap project, was launched in October 2002, with the aim of constructing a genome-wide map of LD and common haplotypes in four populations from Africa, East-Asia and Europe.
THE HAPMAP PROJECT
://www.hapmap.org) adopted a hierarchical mapping strategy. In phase 1 of the project, a map of evenly spaced SNPs (1 per 5 kb) with minor allele frequency greater than or equal to 0.05 is being generated. Analysis of local LD patterns in each population will identify 'haplotype blocks', and also identify the intervening regions that require data from additional SNPs to try to detect LD. Such regions will be the main focus of phase 2, which may include multiple rounds of SNP selection and genotyping. Some additional SNPs will also be typed within the emerging 'haplotype blocks' to corroborate the findings. Work is in progress to develop an optimal statistical approach that describes accurately the highly variable nature of LD, and to provide precise parameters to assess completion of the project in each region of the genome. It is estimated that over 1.6 million SNPs will be tested in the course of the project. Data will be released regularly into the public domain, initially via the consortium's Data Coordination Center (DCC) (http://www.hapmap.org), and from there to dbSNP and other public databases.
What are the HapMap deliverables, and how may they contribute to the advancement of human genetics in general and pharmacogenomics in particular?
At the outset of the HapMap project, it was recognised that the collection of 2.4 million publicly available SNPs (October 2002) was distributed unevenly throughout the human genome, resulting in sparse SNP coverage in many regions. The first deliverable of the HapMap project is therefore the discovery of new SNPs. New shotgun sequence data have been generated across the whole genome, using libraries made from DNA samples of a range of individuals. The sequence data are being aligned to the finished human sequence, and candidate SNPs are being detected using the program SSAHA-SNP. The new data, coupled with improvements to the SNP-calling algorithms, have already made a significant contribution to the current total of 4.5 million SNPs; it is anticipated that this figure will exceed 5.5 million by the end of 2003. Furthermore, the accumulation of sequence data through these efforts made it possible to devise a filter for selecting SNPs that are likely to be common (minor allele frequency 40.05). Over 1.3 million of the currently available SNPs have each allele ascertained by two individual sequence reads. Empirical data confirm that these 'double-hit' SNPs convert to working assays at a much higher rate than random SNPs.
The second deliverable of the HapMap project will be a genome-wide set of SNP assays validated in four populations. SNP assay development and validation remain a costly and labour-intensive exercise; currently, such work needs to be carried out upfront for almost every genetic study undertaken. Like other large-scale genomic projects, The HapMap consortium has set up continuous quality control and assessment of the production pipeline. High throughput genotyping is carried out on five different platforms: MassExtend (Sequenom), Invader (Third Wave), AcycloPrime-FP (Perkin-Elmer), Golden Gate-BeadArray (Illumina) and Parallele. Crosschecking has enabled independent assessment of the performance of the different platforms. Raw genotype data conform to a consistent high standard (499.5% accuracy), based on reproducibility of results in duplicate samples, concordance using independent assays for the same SNP and checks for consistency of allelic inheritance patterns in pedigrees. The HapMap effort to assess genotyping platforms will be of direct relevance to the use of large-scale genotyping for genetic studies in the future.
The third deliverable of the project will be an LD map of the human genome and the determination of the underlying common haplotypes in regions of strong LD. Characterisation of local patterns of LD at high resolution across the genome is a challenging task, owing to both the highly variable nature of LD and the lack of knowledge of the true demographic history of population samples. Current statistical methods, such as various haplotype block definitions, plots of average LD vs physical distance, LDU maps and statistical estimates of recombination rates, all generate different views of LD, which often do not fully overlap. Appropriate training sets for evaluating these methods are being developed, for example, deep re-sequencing of genomic regions and genotyping of all identified variants. However, new tools are likely to be needed and their development, although a priority for the consortium, will be open to the entire field with the prompt release of all raw genotype data. Tools to determine the underlying common haplotypes in each defined region of strong LD are already available. The final product, the haplotype map, will be a valuable tool for choosing optimal marker sets in any study undertaking LD mapping of common complex traits. A fourth deliverable of the HapMap project will thus be a minimal set of reference markers that tag each of the common haplotypes (hence 'haplotype tag SNPs', or htSNPs).
FUTURE BENEFITS/APPLICATIONS
In the course of the next 2 years, the HapMap project will result in a validated set of SNP-based markers that describe local patterns of LD and capture common haplotypes across most of the genome in four populations. Clearly, the applicability of the HapMap in studying variation in populations other than those included in the study will need to be thoroughly tested. As a tool, the HapMap is designed to enable the study of common variants for association to disease and drug response, but it should not be seen in isolation of other resources, for example, a catalogue of all functional variants. Overlaid on the annotated genome sequence, a haplotype map that integrates functional variants will become a very powerful tool for pharmacogenetic and pharmacogenomic studies. Both candidate gene and whole-genome approaches will make use of the HapMap resource to screen common haplotypes for association to a complex genetic trait. The candidate gene approach relies on our knowledge of biochemical pathways and gene interactions, and can be complemented by targeted sequencing to discover rarer variants. As the picture for the major candidates becomes unravelled, the whole-genome approaches will come into their own to find new targets of clinical importance that do not rely on prior hypotheses of gene or protein function. As a result of the concerted use of both approaches, the identification of human sequence variants which alter gene expression and protein function will become a driving force for the development of suitable genotypebased screening methods to support evaluation of new drugs during development and in clinical trials. The importance of concerted international efforts to produce public resources is underlined by the HapMap project, which follows the principles adopted for the human genome sequence itself.
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